Enhanced Pan-antiallergy Vaccine Compositions and Methods

The present inventive concept relates to improved vaccine compositions and methods for inducing immune tolerance, leveraging the original pan-antiallergy vaccine concept to provide enhanced immunogenicity, safety, and efficacy.

The original pan-antiallergy vaccine patent (reference) demonstrated a protein construct comprising a scaffold segment and a motif segment, which showed promise in treating allergies. However, the original construct had limitations in terms of immunogenicity and potential side effects. The present inventive concept addresses these limitations by introducing modifications to the scaffold segment, motif segment, and delivery systems to enhance immunogenicity, reduce IgE binding affinity, and improve safety profiles.

The enhanced vaccine composition comprises the modified protein construct of claim 1, wherein the scaffold segment is engineered to present the motif segment in a multimeric form, increasing immunogenicity. The composition further includes a Toll-like receptor agonist to stimulate immune response. Additionally, the inventive concept encompasses methods for inducing immune tolerance using the modified protein construct, wherein the motif segment is modified to reduce IgE binding affinity. The system for delivering the protein construct employs a nanoparticle-based carrier with a targeting moiety for specific delivery to immune cells. The kit for preparing the protein construct includes a scaffold protein, a motif segment, and instructions for inserting the motif segment into the scaffold protein.

The present inventive concept introduces several novel features that distinguish it from the original patent. Specifically, the modifications to the scaffold segment, motif segment, and delivery systems provide enhanced immunogenicity, safety, and efficacy. The use of Toll-like receptor agonists, nanoparticle-based carriers, and targeting moieties for specific delivery to immune cells are non-obvious improvements over the original patent.

Alternative embodiments of the inventive concept include the use of different scaffold proteins, motif segments, and delivery systems. For example, the scaffold protein could be derived from other bacterial sources, and the motif segment could be modified to target specific allergens. The delivery system could also be adapted for mucosal or transdermal delivery.

The enhanced pan-antiallergy vaccine compositions and methods have significant commercial potential in the allergy treatment market, which is projected to grow to $40 billion by 2025. The inventive concept addresses a critical need for safer and more effective allergy treatments, making it an attractive opportunity for pharmaceutical companies, biotech firms, and research institutions.